



# CORPORATE BACKGROUNDER

## Revolutionizing Science. Transforming Life.


Orbis Health Solutions is a privately-held biotechnology company based in Greenville, South Carolina seeking to improve the lives of people with immune-mediated conditions by developing transformative medicines that target the body's immune system and ignite its natural ability to repair and restore health.

Founded in 2009, Orbis was built upon a bold vision to eradicate cancer and immune-mediated conditions through the development of breakthrough immunotherapies that improve standards of care. Our mission is to develop next-generation immunotherapies that will make a meaningful difference in the lives of patients, caregivers and physicians.

## Founded on Breakthrough Science

Orbis was founded by Dr. Thomas Wagner, an internationally-renowned, award-winning pioneer of biomedical research and molecular biology. Dr. Wagner's personal and scientific journey led him to develop and patent transgenic technology which has revolutionized the way we research cancer today. He was also among the first to develop methods of cell-based therapies, and for the past two decades, Dr. Wagner's research has focused exclusively on the application of modern molecular and cellular biology to the development of new therapies for the treatment of cancer.

Dr. Wagner has served as a scientific advisor to the World Health Organization, to the U.S. Congress, and to the White House under former President Ronald Reagan. Based on over 50 years of Dr. Wagner's breakthrough scientific research and discovery, Orbis' cutting-edge technology can deliver therapeutic opportunities for currently intractable diseases.



Renowned cancer researcher Dr. Thomas Wagner, creator of the TLPLDC therapeutic cancer vaccine.

As one of South Carolina's premier scientific research centers, Orbis has an unparalleled track record when it comes to clinical impact and excellence. Our researchers have collaborated to turn radical ideas into life-changing realities, from creating personalized therapeutic cancer vaccines to an immunology-based serum that regenerates and renews damaged skin.

We believe our unique approach to research leads to new, creative approaches that overcome barriers

and improve clinical outcomes. This combined with our adaptiveness and resourcefulness make Orbis well-suited to tackle and identify innovative and revolutionary solutions to some of medicine's toughest challenges.

## Harnessing the Synergistic Power of the Immune System

Cancer is one of the deadliest diseases that arises from our own cells. This creates a very confusing situation for our immune system. To launch an immune response, the body has to be able to tell the difference between cells that are "self" and "non-self."

One reason cancer is so difficult to treat is that it avoids detection because the immune system thinks it is "self." Without a way for the immune system to tell the difference between a healthy cell and a cancer cell, there is little the body can do to prevent cancer from taking over.

Orbis' technology uses a proprietary particle delivery system that helps the body's immune system recognize foreign invaders as "non-self" allowing it to seek out and to destroy cancer and other immune-mediated conditions.

Orbis has developed a pipeline of immunotherapy-based products that are designed to harness the potent role of the body's innate immune system to repair and to restore health. Each of our product candidates have their own distinct clinical characteristics, target indications, commercialization potential, and unique partnering opportunities.

## Realizing the Promise of Immunotherapy

Orbis' lead product is the TLPLDC (tumor lysate, particle-loaded, dendritic cell) vaccine, an autologous, personalized, therapeutic cancer vaccine designed to stimulate the immune system to recognize tumor cells and fight a patient's specific cancer. Just like every patient is unique, so is every tumor, so it is important to treat each patient's tumor individually.

TLPLDC is an autologous, or personalized, therapeutic cancer vaccine that is made from a patient's own cells and is designed to stimulate the immune system to recognize tumor cells and fight the patient's specific (or unique) cancer.

TLPLDC is currently being investigated as an adjuvant melanoma therapy in patients with a high-risk of recurrence in the monotherapy setting (Phase IIb) and in combination with standard of care checkpoint inhibitor therapy (Phase Ia) at leading academic cancer centers in the United States. Additionally, we are evaluating a Tumor Lysate, Particle Only (TLPO) vaccine, a next generation formulation of TLPLDC, in a 60-patient bridging study aimed at demonstrating equivalency between both products. The TLPO formulation eliminates the need to draw blood and further reduces the time to develop the vaccine, resulting in a more streamlined manufacturing process.

The TLPLDC vaccine has been proven safe through use in more than 300 patients without any toxicity or serious adverse events. Combined with its ability to educate the immune system with a patient's unique tumor-specific antigens, TLPLDC is able to eradicate tumors more

effectively while preventing them from metastasizing and protecting patients from disease recurrence. As a result, we believe TLPLDC has the potential to become an important and foundational therapy for patients with solid tumor cancer.

## Robust Intellectual Property

Orbis' immunotherapy platform is a differentiated and compelling pathway for targeting cancer. Our patent estate includes a large number of issued patents and patent families covering methods and uses of our proprietary immune-mediated technologies, manufacturing processes, and their derivatives. We believe these patents provide substantial competitive advantages and puts Orbis in a strong position to grow the company over the long term, and to bring breakthrough, life-saving therapies to patients in need.

## Strategic Alliances

Orbis has established important alliances with several strategic partners to support clinical development, manufacturing and commercial capabilities.

In an effort to rapidly translate our next-generation of immunotherapies for the treatment of cancer, we conducted extensive research to identify countries with strict regulatory structures that would enable us to treat patients faster while upholding the rigorous standards set forth by the FDA. As a result, Perseus PCI (Personalized Cancer Immunotherapeutics) was established in the Cayman Islands as a wholly-owned subsidiary of Perseus Holdings USA, LLC and as the treatment center for the Company, responsible for conducting the Phase I TLPLDC basket clinical trial in a variety of solid tumor types. Perseus PCI is

investigating the clinical potential of the TLPLDC therapeutic cancer vaccine in 15 different tumor types. In close collaboration with the FDA, the data collected will be used in current and future FDA IND applications. Perseus Holdings USA, LLC controls the master license for the TLPLDC/TLPO immunotherapy platform.

Elios Therapeutics, LLC is the U.S. Sponsor of the ongoing prospective, randomized, double-blind, placebo-controlled Phase IIb clinical trial of the TLPLDC vaccine, the Phase I/IIa checkpoint inhibitor + TLPLDC combination study in the metastatic melanoma setting, and the TLPLDC vs. TLPO bridging study.

We are steadfast in our pursuit of the development of next-generation immunotherapies that will make a meaningful difference in the lives of patients, caregivers and physicians. For more information about our people, science and pipeline, please visit [orbishealthsolutions.com](http://orbishealthsolutions.com).

## At-A-Glance

### Headquarters:

111 Smith Hines Rd, Suites E & F,  
Greenville, SC 29607

**Founded:** 2009

### Founder & Chief

### Scientific Officer:

Thomas E. Wagner, Ph.D.

**President:** Riley Polk

### Number of patents:

More than 200 patents issued  
(53 foundational)

**Facilities:** 7,000 square feet